跳至主要内容
临床试验/NCT06381440
NCT06381440Unknown不适用

Traditional Versus Progressive Robot-assisted Gait Training in People With Multiple Sclerosis and Severe Gait Disability: Study Protocol for a the PROGR-EX Randomized-controlled Trial

University Hospital of Ferrara2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年11月15日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
24
试验地点
2
主要终点
Walking function

研究概览

简要总结

Multiple sclerosis (MS) is a demyelinating neurodegenerative disease. Qualitative alterations in walking function in MS people involve 75% of subjects with MS and are determined by reduced coordination, mobility, balance, and increased risk of falling. Robot assisted gait training (RAGT) devices seem effective in MS patients with severe motor disabilities, failing to show significant superiority when compared to intensive overground gait rehabilitation (OGT). This study aims to evaluate the effects of a low-intensity RAGT at progressively increasing intensity compared to conventional RAGT and OGT.

详细描述

Gait disorders are the most frequent symptoms associated to multiple sclerosis (MS).Robot-assisted gait training (RAGT) in people with MS (PwMS) has been proposed as a possible effective treatment option for severe motor disability. Although RAGT continues to prove effective in increasing patient mobility, no significant superiority was found when compared to intensive overground gait rehabilitation (OGT). In PwMS, RAGT at high-intensity may enhance fatigue and spasticity, compromising the effectiveness and applicability of the intervention.

This study aims to evaluate the effects of a low-intensity RAGT at progressively increasing intensity compared to conventional RAGT and OGT in PwMS and moderate to severe walking impairment.

We will recruit 24 PwMS from the patients afferent to Outpatient Rehabilitation Clinic at University Hospital of Ferrara and we will assign them to one of the three treatment groups: low-intensity RAGT at progressively increasing intensity, conventional RAGT and OGT. All participants will receive 3 weekly treatment sessions of 3 hours each for 4 weeks. In the first 2 hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour, subjects will undergo specific gait training according to the assignment group. Subjects allocated to low-intensity RAGT at progressively increasing intensity group will receive gait rehabilitation on the Lokomat device and a speed initially set at 1.0 km/h, with progressive increments of 0.1 km/h at each training session. The working time consists of bouts of 3 minutes of work alternated by 1 minute of recovery, to be repeated 8 times. Subjects allocated to conventional RAGT will receive gait rehabilitation on the Lokomat device and the machine parameters will be determined based on the patient's characteristics. Subjects allocated to OGT will perform a 40-minute walk on a flat surface supervised by a physiotherapist. Outcomes will be assessed before and after treatment and at 3-month follow-up. The primary outcome is walking speed. Secondary outcomes include mobility and balance, psychological measures, muscle oxygen consumption, electrical and hemodynamic brain activity, urinary biomarkers, usability, and acceptability of robotic devices for motor rehabilitation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of MS (primary or secondary progressive) without relapses in the preceding 3 months
  • Disability rate defined by Expanded Disability Status Scale (EDSS) score from 6 to 7
  • Ability to perform the Timed 25-Foot Walk (T25-FW) test
  • Mini-Mental Status Examination score ≥ 24/30

排除标准

  • Other (neurological) conditions that may affect motor function
  • Medical conditions might interfere with the ability to complete the study protocol safely
  • Presence of spasticity with a Modified Ashworth Scale (MAS) score > 3 or retractions limiting the range of motion of the hip, knee or ankle
  • MS relapses or medication changes or any other confounding factors during the study period
  • Rehabilitation treatment or botulinum toxin injection in the 3 months preceding the start of the study

结局指标

主要结局

Walking function

时间窗: Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).

The walking function will be assessed by the T25-FW test

次要结局

  • Perceived walking ability(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Electrical brain activity(Data changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Fatigue(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Walking endurance(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Spasticity(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Perceived quality of life(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Coping strategies(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Mobility(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Kinesiophobia(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Muscle oxygen consumption(Data changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Hemodynamic cortical activation(Data changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Acceptability of robot intervention(Scores registered after (T1) the twelve sessions of robotic treatment.)
  • Balance(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Anxiety(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Depression(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • Adaptation to medical condition(Score changes before (T0) and after (T1) the twelve sessions of treatment and at 3-months follow-up (T2).)
  • miRNA expression(Data changes before (T0) and after (T1) the twelve sessions of treatment.)

研究者

发起方
University Hospital of Ferrara
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验